Medical News

On March 3, 2020, NHF’s Medical and Scientific Advisory Committee (MASAC) published a letter to the community regarding the evolving coronavirus outbreak. MASAC’s letter seeks to “provide some interim guidance for the bleeding disorders community,” directs people to the CDC website as a reliable source of information, and highlights some information regarding product supply and safety. Among other things, MASAC noted that there have been no indications to date of COVID-19 impacting the supply or quality of bleeding disorders products. MASAC also linked to a statement from the Plasma Protein Therapeutics Association regarding the safety of plasma protein therapies.

HFA notes that the FDA, too, is monitoring the impact of the coronavirus outbreak on drug, biologics, and blood safety and supply. On Feb. 27, 2020, the FDA stated that “there are no shortages of biologics to report at this time” and “there have been no reported cases of transfusion-transmitted COVID-19.”

HFA will continue to publish updates and information about COVID-19 here on our website.

Sign up for E-mails, Dateline Magazine, and other ways to stay connected.